Thank you for subscribing!
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Finfeed Archived Oct 23, 2019
A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.
Finfeed Archived Oct 21, 2019
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
Get expert stock analysis direct in your inbox
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Finfeed Archived Sep 23, 2019
Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.
Finfeed Archived Sep 19, 2019
New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.
Finfeed Archived Sep 11, 2019
The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.
Finfeed Archived Sep 10, 2019
Finfeed has come up with six stocks in the healthcare and bioscience sectors that appear to have plenty going for them in fiscal 2020.
Finfeed Archived Sep 09, 2019
Imagion’s shares received a boost with strong trading throughout the morning resulting in an increase from the previous day’s close of 4.1 cents to 4.5 cents just before midday.
Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).
Finfeed Archived Aug 28, 2019
Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Finfeed Archived Aug 07, 2019
Rhythm Biosciences Ltd (ASX:RHY) is continuing to develop its global, low-cost, lifesaving blood test for the detection of colorectal cancer, ColoSTAT®.
Finfeed Archived Aug 05, 2019
Today, as a man who writes a lot about medical cannabis and related listed companies, my interest is always piqued by medical cannabis based human interest stories.
Next Investors Archived Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
Finfeed Archived May 23, 2019
Drug delivery company Invion Limited (ASX:IVX) is leading the way in developing PhotosoftTM technology for the treatment of a range of cancers.
Next Investors Archived May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Join Our Mailing List
